Abstract:Abstract The microtubule (MT) cytoskeleton is an effective and validated target for cancer chemotherapeutic drugs. Currently, anti-MT drug taxane, e.g. docetaxel, is the first-line chemotherapeutic agent to treat patients with locally advanced or metastatic breast cancer and is also one of the most effective chemotherapeutic agents in clinical use in six different cancers (breast, ovarian, non-small cell lung, prostate, gastric, and head and neck). Nearly half of the treated breast and ovarian cancer patients, however, do not respond to chemotherapy. Although general mechanisms of drug resistance may apply to docetaxel resistance, more specifically, the current research paradigm on docetaxel resistance focus on acquired -tubulin mutations and altered expression of β-tubulin isotypes that interfere with drug target binding. Synuclein gamma (SNCG) is a new unfavorable prognostic marker for breast cancer and a potential target for cancer treatment. At the cellular level, SNCG increases metastasis and promotes genetic instability. At the molecular level, SNCG functions like a tumor specific chaperone and regulates many pathways in growth and progression of cancer, including an interaction with mitotic checkpoint kinase BubR1. Here, we show that expression of SNCG is sufficient to induce specific resistance to docetaxel-caused mitotic arrest and apoptosis in breast cancer cells and in breast cancer xenografts. SNCG binds to spindle checkpoint kinase BubR1, interferes with its interaction with other checkpoint proteins of p55cdc20-APC and Mda2, reduces BubR1's kinase activity, and thus attenuates docetaxel-caused mitotic cell death. The working mechanism of anti-MT drugs heavily relies on the normal function of the checkpoint machinery in which BubR1 is a critical component, this inhibitory effect of SNCG on BubR1 function may lead to the inactivation of checkpoint and thus renders docetaxel resistance. To test the clinical relevance, in a pilot neoadjuvant trial, 20 women with histological proven locally advanced breast cancer were treated with 3 cycles of neoadjuvant TE regimen (docetaxel + epirubicin). SNCG-positive tumors are resistant to anticancer effect of neoadjuvant therapy as assayed by reduction in primary tumor size, an increase in apoptotic index, and a decrease in Ki67 proliferation index. These data show that SNCG renders docetaxel resistance by inhibiting BubR1 activity and is new biomarker for predicting anti-MT drug resistance. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-64.

Docetaxel-induced Human Breast Ccarcinoma Drug-Resistant BT549/Docetaxel Stem Cell Isolation and Adenosine Triphosphate Binding Cassette Transporter G2 Gene Expression Level

Establishment of a docetaxel-induced human breast carcinoma drug-resistant cell line BT549/docetaxel and the mRNA expression of adenosine triphosphate binding cassette transporter G2, adenosine triphosphate binding cassette subfamily B member 1, multidrug

Effect of Down-Regulated Adenosine Triphosphate Binding Cassette Transporter G2 Gene on Human Breast Cancer Docetaxel Resistant Cell Line BT549/Docetaxel

Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of Cd44(+) Cells and Evidence for Epigenetic Mechanisms

Establishment of a Docetaxel-Induced Human Breast Carcinoma Drug-Resistant Cell Line MCF7/docetaxel and Its Biological Characteristics

Cd44(Hi)Cd24(Lo) Mammosphere-Forming Cells From Primary Breast Cancer Display Resistance To Multiple Chemotherapeutic Drugs

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Abstract LB-64: Synuclein Gamma Inhibits BubR1 Function and Renders Resistance to Antimicrotubule Drug

Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7

Establishment and biological characteristics of Taxol-induced drug resistant human lung adenocarcinoma cell line

Establishment and Characterization of a Docetaxel-Resistant Variant of Human Lung Adenocarcinoma Cell Line SPC-A1

Establishment and characterization of a Taxol induced drug-resistant human lung adenocarcinoma cell subline

Mechanism of Drug Resistance Identified in Human Lung Adenocarcinoma Cell Line SPC-A1 Selected for Resistance to Docetaxel

The mechanism of the role of ABC transporters in the multi-drug resistance of SP cells in SPC-A1 cell lines

Isolation and Biological Characterization of Lung Cancer Stem Cells

Establishment of Paclitaxel-Resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo.

The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.

Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line

Establishment of colorectal cancer stem cell-derived tumorspheres and its multi-drug resistance

Tumour stem cells and drug resistance